{"id":"shr-1314","safety":{"commonSideEffects":[{"rate":"null","effect":"Anemia"},{"rate":"null","effect":"Thrombocytopenia"},{"rate":"null","effect":"Neutropenia"}]},"_chembl":{"chemblId":"CHEMBL4298102","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SHR-1314 works by blocking the interaction between CD47 and SIRPα, which is involved in tumor immune evasion. This blockade leads to the activation of immune cells and the elimination of cancer cells.","oneSentence":"SHR-1314 is a small molecule targeting the CD47/SIRPα axis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:59.649Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory multiple myeloma"}]},"trialDetails":[{"nctId":"NCT06860750","phase":"PHASE3","title":"A Trial of SHR-1314 Injection in Adult Patients With Active Non-radiographic Axial Spondyloarthritis","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-04-29","conditions":"Active Non-radiographic Axial Spondyloarthritis","enrollment":380},{"nctId":"NCT06833307","phase":"PHASE3","title":"The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-02","conditions":"Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis","enrollment":90},{"nctId":"NCT05394857","phase":"PHASE2","title":"Efficacy and Safety of SHR-1314 by Subcutaneous Injection in Active Moderate to Severe Graves' Orbitopathy Patients","status":"TERMINATED","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2022-09-13","conditions":"Active Moderate to Severe Graves' Orbitopathy","enrollment":7},{"nctId":"NCT05055934","phase":"PHASE2","title":"Study of the Effectiveness and Safety of SHR-1314 for Psoriatic Arthritis","status":"COMPLETED","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2021-10-22","conditions":"Psoriatic Arthritis","enrollment":112},{"nctId":"NCT06640257","phase":"PHASE3","title":"A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2024-11-04","conditions":"Psoriatic Arthritis","enrollment":200},{"nctId":"NCT06182384","phase":"PHASE1","title":"A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices","status":"COMPLETED","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2023-12-24","conditions":"Moderate-to-Severe Plaque Psoriasis","enrollment":46},{"nctId":"NCT04840485","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2021-06-09","conditions":"Ankylosing Spondylitis","enrollment":548},{"nctId":"NCT03463187","phase":"PHASE1, PHASE2","title":"Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-12-15","conditions":"Moderate-to-severe Chronic Plaque Psoriasis","enrollment":211},{"nctId":"NCT04924296","phase":"PHASE2","title":"A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis","status":"UNKNOWN","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2021-06-28","conditions":"Lupus Nephritis","enrollment":60},{"nctId":"NCT04839016","phase":"PHASE3","title":"Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-04-25","conditions":"Moderate-to-Severe Plaque Psoriasis","enrollment":660},{"nctId":"NCT03704428","phase":"PHASE1","title":"Safety, Tolerability and PK of SHR1314 in axSpA","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2018-04-19","conditions":"Axial Spondyloarthritis","enrollment":45},{"nctId":"NCT04527484","phase":"PHASE1","title":"A Bioequivalence Study to Compare Two Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-08-20","conditions":"Bioequivalence","enrollment":130},{"nctId":"NCT04326881","phase":"PHASE1","title":"A Study to Compare Pharmacokinetic and Safety Profiles of Different Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-04-07","conditions":"Pharmacokinetic","enrollment":30},{"nctId":"NCT04121143","phase":"PHASE2","title":"A Clinical Study of SHR-1314 Injection in the Treatment of Moderate to Severe Plaque Psoriasis in Adults","status":"SUSPENDED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-11-09","conditions":"Plaque Psoriasis","enrollment":120},{"nctId":"NCT03710681","phase":"PHASE1","title":"A Safety Study of Multiple Subcutaneous (s.c.) Injections of SHR-1314 in Adults With Moderate-to-severe Plaque Psoriasis","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2018-08-02","conditions":"Moderate-to-severe Plaque Psoriasis","enrollment":16},{"nctId":"NCT02934412","phase":"PHASE1","title":"A Study of SHR-1314 in Healthy Subjects","status":"COMPLETED","sponsor":"Atridia Pty Ltd.","startDate":"2016-08-22","conditions":"Psoriasis","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo"],"phase":"phase_3","status":"active","brandName":"SHR-1314","genericName":"SHR-1314","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SHR-1314 is a small molecule targeting the CD47/SIRPα axis. Used for Relapsed or refractory multiple myeloma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":9,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}